Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Remdesivir in Severe COVID-19 (Japan, 5-Day vs 10-Day Regimen)
jRCT2080225161Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised trial of remdesivir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Clinical status at Day 14 (7-point ordinal scale). Started Apr 2020; status: completed.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2080225161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225161.